Clinic
Geisinger Wyoming Valley Medical Center
Geisinger Wyoming Valley Medical Center was paid $31.22M by Medicaid between Jan 2018 and Dec 2024, across 486 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoGEISINGER WYOMING VALLEY MEDICAL CENTER
WILKES BARRE, PA 18711
WILKES BARRE, PA 18711
33aNPI1275620585assigned 10/06/2006
33bProvider typeClinic/Center
28Total paid$31.22M
24GClaims1,033,960
24DCodes billed486
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#6 of 176
Median peer was paid$441K
This provider vs. median71×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MULL, CINDY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,643 | $194K | |
| 2019 | 3,941 | $106K | |
| 2020 | 125,819 | $3.89M | |
| 2021 | 362,641 | $11.48M | |
| 2022 | 155,289 | $4.44M | |
| 2023 | 197,010 | $5.51M | |
| 2024incomplete | 186,617 | $5.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 32,628 | 30,954 | $4.40M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 9.4% | 13,711 | 13,198 | $2.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 22,473 | 21,619 | $2.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.3% | 24,311 | 23,550 | $1.66M |
| J9271 | Injection, pembrolizumab, 1 mg | 4.0% | 717 | 543 | $1.26M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.6% | 17,861 | 14,802 | $1.12M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 12,867 | 12,631 | $1.06M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.0% | 15,329 | 12,587 | $949K |
| 80053 | Comprehensive metabolic panel | 3.0% | 90,656 | 83,632 | $942K |
| G0378 | Hospital observation service, per hour | 3.0% | 1,048 | 735 | $932K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 29,426 | 28,585 | $632K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 7,720 | 7,485 | $617K |
474 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 3,310 | $569K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.7% | 657 | $545K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 92,628 | $486K |
| 87631 | 1.4% | 3,242 | $443K | |
| 0100U | 1.4% | 1,102 | $439K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 4,495 | $409K |
| 80061 | Lipid panel | 1.2% | 28,271 | $366K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,704 | $260K |
| 300 | Patient transfer system <300 | <1% | 4,116 | $227K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,371 | $216K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,423 | $211K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,738 | $206K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,035 | $192K |
| 87481 | <1% | 2,744 | $192K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,944 | $181K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,168 | $178K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,185 | $175K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,337 | $170K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,873 | $164K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,282 | $152K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,182 | $145K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,563 | $145K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,115 | $141K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 585 | $130K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,759 | $122K |
| 84484 | <1% | 13,575 | $118K | |
| 76642 | <1% | 1,963 | $109K | |
| 0002A | <1% | 3,033 | $106K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 52,814 | $105K |
| 82607 | <1% | 8,337 | $99K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,777 | $99K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,069 | $98K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,674 | $96K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 459 | $94K |
| 0001A | <1% | 3,112 | $93K | |
| 85027 | <1% | 14,316 | $92K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 374 | $90K |
| 450 | Pov group 1 hd 301-450 lbs | <1% | 198 | $89K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,296 | $88K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 501 | $88K |
| 82728 | <1% | 7,982 | $87K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 527 | $87K |
| 84702 | <1% | 4,960 | $80K | |
| 86803 | <1% | 4,160 | $78K | |
| 87430 | <1% | 11,178 | $70K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 353 | $70K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,890 | $68K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,815 | $67K |
| 80050 | General health panel | <1% | 1,402 | $65K |
| 83540 | <1% | 8,422 | $65K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,193 | $64K |
| 77066 | Tomosynthesis, mammo | <1% | 577 | $64K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 4,678 | $61K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,664 | $60K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,600 | $59K |
| 72141 | <1% | 212 | $58K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 611 | $58K |
| 83690 | <1% | 12,772 | $58K | |
| 31575 | <1% | 917 | $56K | |
| 83880 | <1% | 1,952 | $56K | |
| 76830 | Ultrasound, transvaginal | <1% | 963 | $55K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 206 | $55K |
| 86003 | <1% | 484 | $52K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,116 | $50K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 539 | $47K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 698 | $45K |
| 81025 | <1% | 11,503 | $45K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 573 | $44K |
| 83655 | <1% | 4,037 | $43K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,093 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,843 | $42K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 947 | $42K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,359 | $41K |
| 93320 | <1% | 905 | $41K | |
| 83605 | <1% | 5,916 | $40K | |
| 93971 | <1% | 621 | $39K | |
| 74183 | <1% | 94 | $39K | |
| 80074 | <1% | 764 | $38K | |
| 83550 | <1% | 8,170 | $38K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 170 | $38K |
| 82570 | <1% | 5,776 | $37K | |
| 31231 | <1% | 649 | $36K | |
| 82043 | <1% | 5,017 | $35K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 318 | $33K |
| 71250 | <1% | 444 | $31K | |
| 87511 | <1% | 1,545 | $30K | |
| 76770 | <1% | 528 | $30K | |
| 84439 | <1% | 3,895 | $29K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,478 | $29K |
| 87522 | Neg quan hep c or qual rna | <1% | 724 | $29K |
| 86850 | <1% | 3,705 | $28K | |
| 93970 | <1% | 289 | $28K | |
| 93325 | <1% | 1,672 | $27K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 381 | $27K |
| 77065 | Tomosynthesis, mammo | <1% | 310 | $26K |
| 87150 | <1% | 316 | $26K | |
| 93304 | <1% | 695 | $26K | |
| 87340 | <1% | 1,798 | $26K | |
| 82746 | <1% | 2,228 | $24K | |
| 87506 | <1% | 182 | $24K | |
| 96415 | <1% | 578 | $24K | |
| 83970 | <1% | 631 | $23K | |
| 94729 | <1% | 826 | $23K | |
| 92567 | <1% | 1,930 | $23K | |
| 76536 | <1% | 390 | $22K | |
| 81001 | <1% | 8,251 | $22K | |
| 86618 | <1% | 971 | $22K | |
| 0004A | <1% | 519 | $21K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,186 | $21K |
| 81003 | <1% | 7,241 | $21K | |
| 83735 | <1% | 3,372 | $20K | |
| 95886 | <1% | 699 | $20K | |
| 94726 | <1% | 749 | $19K | |
| 64615 | <1% | 276 | $19K | |
| 86901 | <1% | 4,138 | $19K | |
| 92557 | <1% | 687 | $19K | |
| 86900 | <1% | 4,167 | $19K | |
| 86762 | <1% | 896 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 682 | $18K |
| 85610 | <1% | 5,785 | $18K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 410 | $18K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 364 | $18K |
| 82784 | <1% | 720 | $18K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,479 | $18K |
| 84153 | <1% | 818 | $18K | |
| 88342 | <1% | 415 | $17K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,933 | $17K |
| 93321 | <1% | 779 | $17K | |
| 70486 | <1% | 207 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,331 | $17K |
| 70498 | <1% | 100 | $17K | |
| 88341 | <1% | 178 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 403 | $17K |
| 84403 | <1% | 613 | $16K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 376 | $16K |
| 59899 | <1% | 85 | $15K | |
| 82805 | <1% | 531 | $15K | |
| X0621 | <1% | 73 | $15K | |
| 0012A | <1% | 522 | $14K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 68 | $14K |
| 86317 | <1% | 674 | $14K | |
| 70496 | <1% | 79 | $14K | |
| 92587 | <1% | 406 | $14K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 65 | $14K |
| 86780 | <1% | 886 | $14K | |
| 84146 | <1% | 568 | $13K | |
| 93350 | <1% | 294 | $13K | |
| 87902 | <1% | 70 | $13K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 307 | $13K |
| 70491 | <1% | 116 | $12K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 132 | $12K |
| 86480 | <1% | 200 | $12K | |
| 93296 | <1% | 1,050 | $12K | |
| 87186 | <1% | 1,442 | $11K | |
| 93017 | <1% | 311 | $11K | |
| 96376 | <1% | 234 | $11K | |
| 85046 | <1% | 1,903 | $11K | |
| 80076 | <1% | 1,333 | $11K | |
| 87040 | <1% | 646 | $10K | |
| 86038 | <1% | 722 | $10K | |
| 86140 | <1% | 3,716 | $10K | |
| 73564 | <1% | 462 | $10K | |
| 0072A | <1% | 246 | $10K | |
| 95910 | <1% | 183 | $10K | |
| 0071A | <1% | 236 | $10K | |
| 73610 | <1% | 500 | $10K | |
| 83615 | <1% | 1,543 | $10K | |
| 320 | <1% | 139 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 255 | $9K |
| 83525 | <1% | 830 | $9K | |
| 86592 | <1% | 2,268 | $9K | |
| 85379 | <1% | 945 | $9K | |
| 76801 | <1% | 151 | $9K | |
| 46600 | <1% | 539 | $9K | |
| 82248 | <1% | 1,430 | $9K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 12 | $9K |
| 93880 | <1% | 115 | $8K | |
| 94060 | <1% | 836 | $8K | |
| 96417 | <1% | 139 | $8K | |
| 36591 | <1% | 166 | $8K | |
| C1769 | Guide wire | <1% | 197 | $8K |
| 80081 | <1% | 91 | $8K | |
| 86147 | <1% | 100 | $8K | |
| 73221 | <1% | 25 | $8K | |
| 0064A | <1% | 191 | $8K | |
| 90715 | <1% | 1,307 | $8K | |
| 78264 | <1% | 63 | $7K | |
| 73630 | <1% | 590 | $7K | |
| 76870 | <1% | 140 | $7K | |
| 74018 | <1% | 485 | $7K | |
| 87077 | <1% | 958 | $7K | |
| 84100 | <1% | 1,382 | $7K | |
| 72100 | <1% | 324 | $7K | |
| 84270 | <1% | 274 | $7K | |
| X0616 | <1% | 38 | $7K | |
| 95885 | <1% | 203 | $7K | |
| 83001 | <1% | 386 | $7K | |
| 90686 | <1% | 718 | $7K | |
| 83520 | <1% | 510 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 120 | $7K |
| 73030 | <1% | 413 | $7K | |
| 86039 | <1% | 436 | $6K | |
| 84481 | <1% | 292 | $6K | |
| X0620 | <1% | 34 | $6K | |
| 82950 | <1% | 943 | $6K | |
| 73130 | <1% | 478 | $6K | |
| 87536 | <1% | 58 | $6K | |
| 0011A | <1% | 365 | $6K | |
| 82105 | <1% | 306 | $6K | |
| 84480 | <1% | 787 | $6K | |
| 85730 | <1% | 932 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 170 | $6K |
| 85652 | <1% | 2,038 | $6K | |
| 84145 | <1% | 344 | $6K | |
| 96040 | <1% | 187 | $6K | |
| 85007 | <1% | 1,291 | $5K | |
| 83002 | <1% | 294 | $5K | |
| 87088 | <1% | 625 | $5K | |
| 72197 | <1% | 13 | $5K | |
| 82565 | <1% | 821 | $5K | |
| 84165 | <1% | 394 | $5K | |
| 64405 | <1% | 145 | $5K | |
| 86235 | <1% | 106 | $5K | |
| X0615 | <1% | 26 | $5K | |
| 0003A | <1% | 113 | $5K | |
| 93226 | <1% | 125 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 177 | $5K |
| 76882 | <1% | 311 | $5K | |
| 86431 | <1% | 595 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 280 | $4K |
| 86334 | <1% | 190 | $4K | |
| 77336 | <1% | 123 | $4K | |
| 82962 | <1% | 2,430 | $4K | |
| 87641 | <1% | 144 | $4K | |
| 86200 | <1% | 280 | $4K | |
| 95700 | <1% | 27 | $4K | |
| 82670 | <1% | 182 | $4K | |
| 82785 | <1% | 225 | $4K | |
| 86704 | <1% | 271 | $4K | |
| 10005 | <1% | 59 | $4K | |
| 84630 | <1% | 303 | $4K | |
| 87529 | <1% | 57 | $4K | |
| 78227 | <1% | 12 | $4K | |
| 86800 | <1% | 209 | $4K | |
| 84550 | <1% | 647 | $4K | |
| 87338 | <1% | 264 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 66 | $4K |
| 95909 | <1% | 90 | $4K | |
| 73590 | <1% | 214 | $4K | |
| 86225 | <1% | 245 | $4K | |
| 69210 | <1% | 207 | $4K | |
| 95819 | <1% | 263 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 113 | $3K |
| 96411 | <1% | 52 | $3K | |
| 49083 | <1% | 63 | $3K | |
| 74178 | <1% | 16 | $3K | |
| 93922 | <1% | 158 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 53 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,146 | $3K |
| 85018 | <1% | 1,022 | $3K | |
| 72158 | <1% | 24 | $3K | |
| 88185 | <1% | 19 | $3K | |
| 73110 | <1% | 261 | $3K | |
| 83921 | <1% | 187 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 160 | $3K |
| 84450 | <1% | 464 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 383 | $3K |
| 82550 | <1% | 493 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,034 | $3K |
| 80164 | <1% | 174 | $3K | |
| 96402 | <1% | 71 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 343 | $3K |
| 73502 | <1% | 161 | $3K | |
| 80197 | <1% | 237 | $3K | |
| 87070 | <1% | 422 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,383 | $3K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,954 | $3K |
| 84460 | <1% | 356 | $3K | |
| 82375 | <1% | 584 | $2K | |
| X0592 | <1% | 60 | $2K | |
| 92556 | <1% | 154 | $2K | |
| 86376 | <1% | 303 | $2K | |
| 92588 | <1% | 39 | $2K | |
| 83721 | <1% | 210 | $2K | |
| 80069 | <1% | 329 | $2K | |
| 12001 | <1% | 104 | $2K | |
| 82247 | <1% | 322 | $2K | |
| 82525 | <1% | 188 | $2K | |
| 36430 | <1% | 97 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 72 | $2K |
| 73090 | <1% | 160 | $2K | |
| 93225 | <1% | 130 | $2K | |
| 74022 | <1% | 77 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 286 | $2K |
| 82533 | <1% | 183 | $2K | |
| 0013A | <1% | 52 | $2K | |
| 86708 | <1% | 129 | $2K | |
| 86360 | <1% | 36 | $2K | |
| 82951 | <1% | 149 | $2K | |
| 84156 | <1% | 524 | $2K | |
| 95816 | <1% | 152 | $2K | |
| 95911 | <1% | 29 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,469 | $2K |
| 84425 | <1% | 277 | $2K | |
| 86787 | <1% | 107 | $2K | |
| 83090 | <1% | 102 | $2K | |
| 0296T | <1% | 34 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12,109 | $2K |
| 76885 | <1% | 16 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,993 | $2K |
| 77334 | <1% | 20 | $2K | |
| 73080 | <1% | 130 | $2K | |
| 86359 | <1% | 36 | $1K | |
| 82627 | <1% | 66 | $1K | |
| 86160 | <1% | 48 | $1K | |
| 84590 | <1% | 113 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,711 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,632 | $1K |
| 84520 | <1% | 298 | $1K | |
| 86617 | <1% | 30 | $1K | |
| 92552 | <1% | 164 | $1K | |
| 80177 | <1% | 112 | $1K | |
| 82040 | <1% | 408 | $1K | |
| 88173 | <1% | 126 | $1K | |
| 77001 | <1% | 28 | $1K | |
| 86335 | <1% | 47 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 912 | $1K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 43 | $1K |
| C1729 | Catheter, drainage | <1% | 180 | $1K |
| 87493 | <1% | 33 | $1K | |
| 96523 | <1% | 79 | $1K | |
| 82803 | <1% | 58 | $1K | |
| 83021 | <1% | 58 | $1K | |
| 83050 | <1% | 512 | $1K | |
| 83516 | <1% | 78 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 172 | $1K |
| 82150 | <1% | 253 | $1K | |
| 99152 | <1% | 126 | $1K | |
| 80179 | <1% | 83 | $1K | |
| 82977 | <1% | 124 | $997.46 | |
| 86665 | <1% | 26 | $989.44 | |
| 87205 | <1% | 237 | $979.23 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 999 | $937.55 |
| 81513 | <1% | 14 | $932.48 | |
| 82947 | <1% | 231 | $890.45 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 820 | $884.32 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,426 | $883.86 |
| 87075 | <1% | 99 | $865.59 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,319 | $858.46 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 70 | $856.99 |
| 86255 | <1% | 51 | $851.30 | |
| 88307 | <1% | 30 | $833.37 | |
| 12011 | <1% | 27 | $825.40 | |
| 31579 | <1% | 13 | $783.38 | |
| 81000 | <1% | 190 | $768.68 | |
| 84075 | <1% | 116 | $751.10 | |
| 86923 | <1% | 32 | $728.70 | |
| 76942 | <1% | 13 | $716.84 | |
| 88142 | <1% | 41 | $688.00 | |
| 36416 | <1% | 781 | $681.12 | |
| 93308 | <1% | 27 | $660.04 | |
| 51798 | <1% | 51 | $641.44 | |
| 86696 | <1% | 28 | $616.29 | |
| 80178 | <1% | 90 | $611.76 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,028 | $595.99 |
| 74230 | <1% | 25 | $592.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,077 | $588.17 |
| 83010 | <1% | 60 | $570.49 | |
| 73140 | <1% | 53 | $566.78 | |
| 84112 | <1% | 14 | $529.83 | |
| 86695 | <1% | 28 | $524.76 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,652 | $524.67 |
| 82465 | <1% | 81 | $511.52 | |
| 80325 | <1% | 32 | $488.10 | |
| 86694 | <1% | 27 | $473.99 | |
| 94010 | <1% | 61 | $473.07 | |
| 72040 | <1% | 26 | $462.20 | |
| 87046 | <1% | 184 | $449.45 | |
| 82330 | <1% | 62 | $442.39 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,856 | $405.61 |
| 82310 | <1% | 71 | $405.27 | |
| 82952 | <1% | 121 | $401.67 | |
| 88184 | <1% | 12 | $400.34 | |
| 86769 | <1% | 37 | $400.04 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 484 | $387.84 |
| 88172 | <1% | 15 | $387.20 | |
| 87328 | <1% | 46 | $369.42 | |
| 76937 | <1% | 15 | $364.88 | |
| 97162 | <1% | 14 | $359.41 | |
| 80175 | <1% | 25 | $343.03 | |
| 82077 | <1% | 63 | $341.92 | |
| 93246 | <1% | 16 | $340.50 | |
| 73552 | <1% | 26 | $336.63 | |
| 84155 | <1% | 73 | $333.43 | |
| 84402 | <1% | 12 | $326.39 | |
| 85014 | <1% | 100 | $302.62 | |
| 84681 | <1% | 12 | $302.03 | |
| 10060 | <1% | 13 | $298.09 | |
| 29125 | <1% | 12 | $285.74 | |
| 72050 | <1% | 12 | $285.28 | |
| 83521 | <1% | 14 | $282.64 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 286 | $270.77 |
| 73060 | <1% | 24 | $268.35 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 741 | $261.70 |
| 84132 | <1% | 44 | $260.51 | |
| 83883 | <1% | 15 | $254.52 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,290 | $247.90 |
| 83498 | <1% | 12 | $247.88 | |
| 86664 | <1% | 12 | $241.38 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,298 | $232.59 |
| 82140 | <1% | 65 | $232.24 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 873 | $230.45 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 35 | $224.65 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 741 | $217.09 |
| 91200 | <1% | 15 | $212.20 | |
| 84163 | <1% | 12 | $207.30 | |
| 86705 | <1% | 12 | $193.14 | |
| 86735 | <1% | 12 | $182.58 | |
| 85613 | <1% | 13 | $141.54 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,546 | $137.10 |
| 20552 | <1% | 24 | $136.00 | |
| 11721 | <1% | 15 | $132.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 43 | $131.15 |
| 86765 | <1% | 12 | $128.60 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 13 | $121.58 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,065 | $118.37 |
| 87102 | <1% | 15 | $113.40 | |
| 86870 | <1% | 12 | $107.50 | |
| 85520 | <1% | 15 | $105.63 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 32 | $100.22 |
| 87206 | <1% | 32 | $99.75 | |
| 86308 | <1% | 15 | $98.91 | |
| 81002 | <1% | 27 | $87.94 | |
| 92555 | <1% | 12 | $82.74 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 201 | $80.24 |
| J1815 | Injection, insulin, per 5 units | <1% | 913 | $77.25 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 694 | $68.71 |
| 80143 | <1% | 12 | $68.20 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 17 | $64.08 |
| 88304 | <1% | 12 | $55.74 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 445 | $54.88 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 14 | $47.99 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 148 | $40.58 |
| 87147 | <1% | 14 | $30.52 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 140 | $25.37 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 12 | $13.76 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 121 | $4.73 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 240 | $1.13 |
| 93797 | 0% | 117 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 80 | $0.00 |
| 90375 | 0% | 12 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 130 | $0.00 |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 0% | 55 | $0.00 |
| J3490 | Unclassified drugs | 0% | 51 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 120 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 51 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 77 | $0.00 |
| 90656 | 0% | 69 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 13 | $0.00 |
| 90677 | 0% | 15 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 13 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 87 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 334 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 356 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 299 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 148 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 13 | $0.00 |
| 90675 | 0% | 18 | $0.00 | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 0% | 117 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 129 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 28 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMULL, CINDY (SYSTEM DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Geisinger Clinic | Danville, PA | $74.54M |
| Community Medical Center | Scranton, PA | $22.62M |
| Geisinger Clinic | Danville, PA | $14.93M |
| West Shore Advanced Life Support Services, INC. | Danville, PA | $4.41M |
| Geisinger Clinic | Pottsville, PA | $3.39M |
| Geisinger Clinic | Lewistown, PA | $2.93M |
| Geisinger Clinic | Scranton, PA | $2.63M |
| Geisinger Clinic | Wilkes Barre, PA | $2.35M |
| Geisinger Clinic | Danville, PA | $2.28M |
| Geisinger Jersey Shore Hospital | Jersey Shore, PA | $2.17M |
| Geisinger Clinic | Scranton, PA | $1.71M |
| Geisinger Clinic | Tunkhannock, PA | $1.11M |
| Geisinger Clinic | Orwigsburg, PA | $974K |
| Geisinger Clinic | Pittston, PA | $942K |
| Geisinger Clinic | Berwick, PA | $896K |
| Geisinger Clinic Selinsgrove | Selinsgrove, PA | $819K |
| Geisinger Clinic | Philipsburg, PA | $678K |
| Geisinger Clinic | Lewisburg, PA | $557K |
| Geisinger Clinic | Mountain Top, PA | $523K |
| Geisinger Clinic | Kulpmont, PA | $489K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.